Insulet Co. (NASDAQ:PODD) Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lowered its position in Insulet Co. (NASDAQ:PODD) by 14.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 344,164 shares of the medical instruments supplier’s stock after selling 59,698 shares during the period. Fisher Asset Management LLC owned approximately 0.49% of Insulet worth $74,677,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC boosted its position in Insulet by 2,680.0% in the fourth quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 134 shares during the last quarter. Parkside Financial Bank & Trust boosted its position in Insulet by 251.0% in the third quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 123 shares during the last quarter. Allworth Financial LP boosted its position in Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 92 shares during the last quarter. Lindbrook Capital LLC boosted its position in Insulet by 64.1% in the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock worth $42,000 after purchasing an additional 75 shares in the last quarter. Finally, BluePath Capital Management LLC purchased a new stake in Insulet in the 3rd quarter worth approximately $31,000.

Insider Activity at Insulet

In related news, Director Shacey Petrovic sold 11,609 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at approximately $418,215.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.47% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms have commented on PODD. Stifel Nicolaus upped their price objective on Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a research report on Monday, February 5th. Piper Sandler lowered their price objective on Insulet from $250.00 to $230.00 and set an “overweight” rating on the stock in a research report on Friday, February 23rd. Barclays lowered their price objective on Insulet from $214.00 to $213.00 and set an “equal weight” rating on the stock in a research report on Monday, February 26th. Finally, JPMorgan Chase & Co. upped their price objective on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

Insulet Stock Up 0.6 %

NASDAQ PODD opened at $174.43 on Friday. The business has a fifty day moving average price of $169.57 and a 200 day moving average price of $180.68. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. The company has a market cap of $12.21 billion, a P/E ratio of 59.94, a P/E/G ratio of 3.12 and a beta of 1.00.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 EPS for the quarter, beating the consensus estimate of $0.67 by $0.73. Insulet had a return on equity of 32.19% and a net margin of 12.16%. The firm had revenue of $509.80 million during the quarter, compared to the consensus estimate of $461.26 million. During the same period in the prior year, the company earned $0.55 EPS. The firm’s revenue was up 37.9% compared to the same quarter last year. Research analysts anticipate that Insulet Co. will post 3.08 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.